噬菌体连接抗菌药物耐药性的生物学环节:从起源与传播到替代治疗方案
综述阐述噬菌体在抗菌药物耐药性(AMR)中的双重角色:一方面主要通过转导促进AMR传播,并可能间接参与接合与转化,噬菌体-质粒在AMR进化中受关注;另一方面噬菌体疗法通过裂解活性和酶降解靶向多重耐药病原体并破坏生物膜,但面临噬菌体耐药、宿主特异性和监管限制等挑战,需与现有抗菌策略整合。
要点
- 噬菌体主要通过转导传播AMR,并可能间接参与接合与转化。
- 噬菌体-质粒是连接噬菌体与质粒、推动AMR进化的动态实体。
- 噬菌体疗法可靶向多重耐药病原体并破坏生物膜,但存在耐药与监管挑战。
核心结论
- 噬菌体既参与AMR的产生与传播,也可能在联合抗生素的情况下促进AMR的解决。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 噬菌体主要通过转导促进AMR传播,新证据提示其间接参与接合与转化。
- 噬菌体-质粒在AMR进化中的作用受到越来越多关注。
- 噬菌体疗法通过裂解活性和酶降解靶向多重耐药病原体并破坏生物膜。
- 噬菌体疗法面临噬菌体耐药、宿主特异性和监管限制等挑战。
关键数值与推荐
- 2015年EMA研讨会等举措寻求建立噬菌体疗法监管审批路径,涉及噬菌体标准化、生产、质量控制、临床验证和产品监测。
- 东欧国家已将噬菌体疗法成功整合进医疗实践,其经验可能加速西方医疗体系接受。
临床怎么用
- 可将噬菌体与现有抗菌策略整合,作为应对AMR的可行方法。
- 临床推广噬菌体疗法需解决噬菌体耐药、宿主特异性和监管约束等问题。
局限性
- 许多地区噬菌体疗法监管框架仍不完善。
- 噬菌体耐药、宿主特异性和监管约束限制广泛临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance (AMR) poses a severe global health threat, necessitating alternatives to conventional antibiotics, which are increasingly ineffective. Phages play a dual role in both propagating and potentially mitigating AMR. They facilitate AMR dissemination primarily through transduction, with emerging evidence suggesting indirect involvement in conjugation and transformation. Phage-plasmids, a dynamic entity bridging phages and plasmids, have gained increasing attention for their role in AMR evolution. Conversely, phage therapy has demonstrated promise in targeting MDR pathogens and disrupting biofilms through lytic activity and enzymatic degradation. However, challenges, such as phage resistance, host specificity and regulatory constraints, must be addressed to enable widespread clinical implementation. While regulatory frameworks for phage therapy remain underdeveloped in many regions, initiatives such as the EMA workshop in 2015 have sought to establish pathways for regulatory approval, addressing issues related to phage standardization, phage production, quality control, clinical validation and product monitoring. Leveraging the extensive experience of Eastern European countries, where phage therapy has been successfully integrated into medical practice, may accelerate its acceptance in Western healthcare systems. Integrating phages with existing antimicrobial strategies may provide a viable approach to combating AMR. Phages thus connect the biological dots of AMR by contributing to its generation and spread, but possibly also to its resolution, likely in combination with antibiotics.
引用
- Anastassopoulou C, Panagiotopoulos AP, Ferous S, et al. Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules. J Antimicrob Chemother. 2025. PMID: 40794809. doi:10.1093/jac/dkaf293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。